Search results for "Hepatitis C virus"
USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection with moderate certainty
An essential requirement of expanded screening is the availability of effective treatment, but randomized controlled trials to date have not shown clinical benefit of direct-acting antiviral therapy beyond sustained virologic response, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/07/24/7.htm
24 Jul 2020
Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response
A commentary in ACP Journal Club noted that while screening and treating all patients with chronic hepatitis C virus (HCV) would be cost-effective and probably cost-saving, some payers are still resistant.
https://gastroenterology.acponline.org/archives/2017/07/28/11.htm
28 Jul 2017
Alcohol abstinence not required for direct-acting antivirals to cure HCV, study finds
Restricting access to direct-acting antiviral therapy because of alcohol use creates an unnecessary barrier for patients with hepatitis C virus (HCV) infection, according to the authors of a recent study.
https://gastroenterology.acponline.org/archives/2023/10/27/1.htm
27 Oct 2023
About one-third of Americans with HCV had evidence of viral clearance in past decade
The highest proportion of hepatitis C virus (HCV) cure or clearance among all age groups and payers was 49% among commercially insured patients ages 60 years and older, a study found.
https://gastroenterology.acponline.org/archives/2023/07/28/6.htm
28 Jul 2023
ID, liver societies update guidance for HCV testing, management
Major changes to guidance on hepatitis C virus (HCV) include an emphasis on universal screening, new recommendations for managing incomplete treatment adherence, and expansion of treatment eligibility, among others.
https://gastroenterology.acponline.org/archives/2023/06/23/6.htm
23 Jun 2023
MKSAP Quiz: Hepatocellular carcinoma surveillance after HCV treatment
This month's quiz asks readers to determine the most appropriate biannual surveillance modality for a 62-year-old patient with compensated cirrhosis who was treated for hepatitis C virus (HCV) infection six months ago.
https://gastroenterology.acponline.org/archives/2021/10/22/4.htm
22 Oct 2021
HCV medications decreased liver disease among those using injection drugs
A Baltimore-based study found that half of participants with chronic hepatitis C virus (HCV) and a history of injection drug use at baseline were free of the virus by 2019, with associated reductions in their risk of cirrhosis and mortality.
https://gastroenterology.acponline.org/archives/2022/07/22/2.htm
22 Jul 2022
HCV treatment effective, but underutilized, studies show
One study found that re-infection rates are low after successful hepatitis C virus (HCV) treatment in people who inject drugs, while another found that use of direct-acting antivirals in patients diagnosed with HCV is low, regardless of insurance status.
https://gastroenterology.acponline.org/archives/2022/08/26/3.htm
26 Aug 2022
Spotlight on improving HCV care
A systematic review and meta-analysis assessed which interventions may improve hepatitis C virus (HCV) testing, linkage to care, and treatment initiation, while a randomized trial found that an accessible care model may be superior to facilitated referral at curing HCV in individuals who inject drugs.
https://gastroenterology.acponline.org/archives/2022/03/25/5.htm
25 Mar 2022
Patients had high adherence to HCV treatment delivered in opioid agonist therapy programs
The hepatitis C virus (HCV) treatment completion rate was 97% among all participants, including those actively using drugs.
https://gastroenterology.acponline.org/archives/2019/04/26/6.htm
26 Apr 2019